prime project 1.4 patient safety in the ambulatory care … · web viewprime project 1.4 patient...

Project 1.4 Patient Safety in the Ambulatory Care Setting Metric Specification Manual v2.0

PRIME Project 1.4 Patient Safety in the Ambulatory Care Setting Metric Specification Manual v2.1

Document Control Log

Version

Date

Details

V1.0

2/29/16

Metric specifications not arranged by Project

Metric specifications in native format without editing

V2.0

3/7/16

Metrics arranged by Project

Metric specifications edited for PRIME

V2.1

4/29/16

Added PRIME Eligible Population for DMPHs

Added sentence requiring inclusion of individuals who meet either Population #1or

#2 criteria.

Modified continuous enrollment language for PRIME Eligible Population #2 to be

12 months during the Measurement Period

Replaced “Appendix 2” with “Table 5” in GPP footnote

Deleted reporting of three rates in 1.4.2 NQF 2371

Revised specification and Summary Table for 1.4.1 Abnormal Results Follow-up

V2.2

5/31/16

Approved by DHCS

Added exclusion of inpatient encounters in PRIME Eligible Population #1

Added PRIME Eligible Population Tenure and Exclusion criteria

Revised summary table for 1.4.1 to align with measure numerator/denominator

Removed the word “abnormal” in 1.4.1 denominator to align with the INR &

mammogram denominators in the same metric.

Added Exclusions and definition of “Ambulatory Care Tests/Ambulatory Setting” in

1.4.1 Abnormal Results Follow-up

Added “INR Test” and “Interval” language from original specs to Numerator Details

under 1.4.3 NQF 0555

V2.3

6/30/16

Approved by DHCS

Added time criteria to PRIME Eligible Population incarceration exclusion

Added specifications for look back period for 1.4.1 BIRADS 1-3 follow-up.

Defined the Index and follow-up mammogram measurement periods in 1.4.1 for each DY

for BIRADS 1-3 follow-up

Removed link to Metric Question Form

Measurement Periods

Demonstration Year

Mid-Year Report Measurement Period

Final Year-End Report Measurement Period

DY 11

Not applicable

Jul 1, 2015 – Jun 30, 2016

DY12

Jan 1, 2016 – Dec 31, 2016

Jul 1, 2016 – Jun 30, 2017

DY13

Jan 1, 2017 – Dec 31, 2017

Jul 1, 2017 – Jun 30, 2018

DY14

Jan 1, 2018 – Dec 31, 2018

Jul 1, 2018 – Jun 30, 2019

DY15

Jan 1, 2019 – Dec 31, 2019

Jul 1, 2019 – Jun 30, 2020

Note: Specifications for PRIME measures that are CMS Core measures refer to CMS value sets[footnoteRef:1] [1: A CMS value set is the complete set of codes used to identify a service or condition included in a measure. The value set references are underlined in the specifications (e.g. BMI Percentile Value Set). The Value Set Directory is available at: http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Quality-of-Care/Downloads/2015-Adult-Value-Set-Directory.zip, Accessed on 2/26/2016. For a Value Set Directory User Manual, refer to Appendix A in the 2015 Core Set of Adult Health Care Quality Measures for Medicaid.]

PRIME Eligible Population for Designated Public Hospitals (DPHs) only:

The PRIME Eligible Population includes the combination of both Population #1 and Population #2. An individual does not have to meet criteria of both Population #1 and Population #2. Any individual who meets either PRIME Eligible Population #1 criteria or PRIME Eligible Population #2 criteria must be included in the PRIME Eligible Population.

Population #1:

Individuals of all ages with at least 2 encounters with the PRIME Entity Primary Care team during the measurement period.

· A Primary Care team encounter is counted if occurred with a member of the Primary Care Team from Family Medicine, Internal Medicine, or Pediatrics. The PRIME Entity may choose to include populations who are seen for primary care in a specialty clinic (e.g. HIV)

· Encounters include either a face-to-face visit with a primary care provider OR any encounter included in the list of eligible non-traditional service types described in the Global Payment Program[footnoteRef:2] (for PRIME, encounters not limited to uninsured individuals.) [2: Non-traditional service encounters as listed in California’s MediCal 2020 Special Terms and Conditions Attachment FF: Global Payment Program Valuation Protocol, Table 5: Categories of Service and Point Values, Non-Traditional]

· Only encounters with the Primary Care team in the ambulatory setting will be counted toward the above 2 encounter requirement. Encounters with primary care team members in the inpatient setting do not count toward the two primary care encounter requirement. [This does not impact the expansion of the PRIME Eligible Population to include inpatient or acute care utilization as specified by the Project Target Population criteria e.g. in Domain 3]

Population #2

Individuals of all ages who are in Medi-Cal Managed Care with 12 months of continuous assignment to the PRIME Entity during the Measurement Period.

· No more than one gap in enrollment or assignment with the PRIME Entity of up to 45 days during the Measurement Period.

· Individual must be enrolled in the primary plan and assigned to the PRIME Entity on the final day of the Measurement Period.

PRIME Eligible Population for District Municipal Hospitals (DMPHs) only:

The PRIME Eligible Population is all individuals with at least two encounters by the participating PRIME entity among Medi-Cal Beneficiaries.

Tenure Criteria for DPH/DMPH PRIME Eligible Population Encountered Lives

1. The first of the two required primary care encounters (DPH) or Medi-Cal encounters (DMPH) must occur during the first 6 months of the measurement period

2. The second required (primary care) encounter may occur at any point during the measurement period.

3. The two (primary care) encounters during the measurement period fulfilling the PRIME Eligible Population eligibility criteria cannot occur on the same day.

Exclusion Criteria for DPH/DMPH PRIME Eligible Population

Exclusion for patients no longer the responsibility of the PRIME Entity at the end of the measurement period:

1. Any patient meeting the PRIME Eligible Population Encountered Lives criteria in a given measurement period who then experiences any of the following scenarios, will be removed from the PRIME Eligible Population for that measurement period, when the PRIME entity has documentation that before the end of the measurement period:

a. The patient has died.

b. The patient has changed their care to a PCP in a health system that is not the PRIME Entity.

c. The patient has had a total time of incarceration during the measurement period that exceeded 45 days, regardless of the number of times the individual was incarcerated during the measurement period.

PRIME Project 1.4 Target Population is the PRIME Eligible Population as defined above.

Summary Table

This table does not contain all the criteria for the numerator and denominator. Adhere to the metric specification.

1.4.2 - NQF 2371: Annual Monitoring for Patients on Persistent Medications

Specification Source: : 2015 Core Set of Adult Health Care Quality Measures for Medicaid v. April 2015

Numerator: This measure is reported as a total rate. For annual monitoring for patients on ACE inhibitors or ARBs: the number of patients with at least one serum potassium and serum creatinine therapeutic monitoring test in the measurement year. For annual monitoring for patients on digoxin: the number of patients with at least one serum potassium, one serum creatinine, and a serum digoxin therapeutic monitoring test in the measurement year. For annual monitoring for patients on diuretics: the number of patients with at least one serum potassium and serum creatinine therapeutic monitoring test in the measurement year. For the total rate: sum of the 3 numerators.

Denominator: Patients age 18 and older as of the end of the measurement year who are on selected persistent medications (ACE Inhibitors/ARB, Digoxin or Diuretics.)

1.4.1 - Abnormal results follow-up: % of abnormal results with appropriate and timely documentation and follow-up

Specification Source: PRIME Innovative Measure Steward

Numerator: Number of denominator serum Potassium, INR tests or mammograms that have had appropriate follow-up

Denominator: The number of serum potassium, INR tests or mammograms completed in the ambulatory setting during the measurement year in PRIME Eligible Population patients age 18 and older, as of the end of the measurement period, who are on selected persistent medications (ACE Inhibitors/ARB, Diuretics, or Warfarin), or who was assessed for breast cancer with a mammogram.

1.4.3 - NQF 0555: INR Monitoring for Individuals on Warfarin

Specification Source: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Downloads/NQF-0555.zip

Numerator: The number of individuals in the denominator who have at least one INR monitoring test during each 56-day interval with active warfarin therapy.

Denominator:

Individuals at least 18 years of age as of the beginning of the measurement period with warfarin therapy for at least 56 days during the measurement period.

1.4.2 - NQF 2371 Annual Monitoring for Patients on Persistent Medications

MEASURE MPM-AD: ANNUAL MONITORING FOR PATIENTS ON PERSISTENT

MEDICATIONS

National Committee for Quality Assurance

A. DESCRIPTION

Percentage of individuals in the Project 1.4 Target Population age 18 and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year. Report as a total rate.

•Annual monitoring for individuals on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB)

•Annual monitoring for individuals on digoxin

•Annual monitoring for individuals on diuretics

•Total rate (the sum of the three numerators divided by the sum of the three denominators)

Data Collection Method: Administrative

Guidance for Reporting:

• This measure applies to individuals in the Project 1.4 Target Population age 18 and older.

• Include all paid, suspended, pending, and denied claims.

• NCQA’s list of NDC codes for ACE Inhibitors/ARBs can be found at:

http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2015/HEDIS2

015NDCLicense/HEDIS2015FinalNDCLists.aspx

B. ELIGIBLE POPULATION

Age

Age 18 and older as of the last day of the measurement period

PRIME Project 1.4 Patient Safety in the Ambulatory Care SettingMetric Specification Manual V2.3

Return to Summary Table Page 18 of 19v2.3 6/30/16, DHCS Approved

(Measure MPM-AD: Annual Monitoring for Patients on Persistent Medications) (5)

Event/

Diagnosis

Individuals on persistent medications (i.e., Individuals who received at least 180 treatment days of ambulatory medication in the measurement year). Refer to Additional Eligible Population Criteria for each rate.

Treatment days are the actual number of calendar days covered with prescriptions within the measurement period (i.e., a prescription of 90 days’ supply dispensed on first day of the last month of the measurement year counts as 30 treatment days). Sum the days’ supply for all medications and subtract any days’ supply that extends beyond the last day of the measurement period.

Note: Medications dispensed in the year prior to the measurement year must be counted toward the 180 treatment days.

C. ADMINISTRATIVE SPECIFICATION

Report as a total rate. The total rate is the sum of the three numerators divided by the sum of the three denominators.

Rate 1: Annual Monitoring for Individuals on ACE Inhibitors or ARBs

Additional Eligible Population Criteria

Individuals who received at least 180 treatment days of ACE inhibitors or ARBs, during the measurement year. Refer to Table MPM-A (which corresponds to NDC code Table CDC-L) to identify ACE inhibitors and ARBs.

Individuals may switch therapy with any medication listed in Table MPM-A during the measurement year and have the day’s supply for those medications count toward the total 180 treatment days (i.e., an individual who received 90 days of ACE inhibitors and 90 days of ARBs meets the denominator definition for rate 1).

Table MPM-A. ACE Inhibitors/ARBs

Description

Prescription

Angiotensin converting enzyme inhibitors

Benazepril Captopril Enalapril Fosinopril

Lisinopril Moexipril Perindopril Quinapril

Ramipril

Trandolapril

Angiotensin II

inhibitors

Azilsartan Candesartan Eprosartan Irbesartan

Losartan Olmesartan Telmisartan Valsartan

.

Description

Prescription

Antihypertensive combinations

Aliskiren-valsartan Amlodipine-benazepril Amlodipine-

hydrochlorothiazide-

valsartan

Amlodipine- hydrochlorothiazide- olmesartan

Amlodipine- olmesartan

Amlodipine- telmisartan

Amlodipine-valsartan

Azilsartan- chlorthalidone

Benazepril- hydrochlorothiazide

Candesartan- hydrochlorothiazide

Captopril- hydrochlorothiazide

Enalapril- hydrochlorothiazide

Eprosartan- hydrochlorothiazide

Fosinopril- hydrochlorothiazide

Hydrochlorothiazide- irbesartan

Hydrochlorothiazide- lisinopril

Hydrochlorothiazide

-losartan

Hydrochlorothiazide

-moexipril

Hydrochlorothiazide

-olmesartan

Hydrochlorothiazide

-quinapril

Hydrochlorothiazide

-telmisartan

Hydrochlorothiazide

-valsartan

Trandolapril- verapamil

Numerator

At least one serum potassium and a serum creatinine therapeutic monitoring test in the measurement year. Any of the following during the measurement year meet criteria:

•A lab panel test (Lab Panel Value Set)

•A serum potassium test (Serum Potassium Value Set) and a serum creatinine test

(Serum Creatinine Value Set)

The tests do not need to occur on the same service date, only within the measurement year.

Rate 2: Annual Monitoring for Individuals on Digoxin


Individuals who received at least 180 treatment days of digoxin (Table MPM-B) during the measurement year.

Table MPM-B. Drugs to Identify Individuals on Digoxin

Description

Prescription

Inotropic agents

Digoxin

Numerator

At least one serum potassium, at least one serum creatinine, and at least one serum

digoxin therapeutic monitoring test in the measurement year. Any of the following during the measurement period meet criteria:

• A lab panel test (Lab Panel Value Set) and a serum digoxin test (Digoxin Level Value

Set).

• A serum potassium test (Serum Potassium Value Set), and a serum creatinine test

(Serum Creatinine Value Set) and a serum digoxin test (Digoxin Level Value Set).

The tests do not need to occur on the same service date, only within the measurement period.

Rate 3: Annual Monitoring for Individuals on Diuretics


Individuals who received at least 180 treatment days of a diuretic (Table MPM-C), during the measurement year.

Individuals may switch therapy with any medication listed in Table MPM-C during the measurement year and have the day’s supply for those medications count toward the total 180 treatment days.

Table MPM-C. Drugs to Identify Individuals on Diuretics

Description

Prescription

Antihypertensive combinations

Aliskiren-hydrochlorothiazide

Aliskiren-hydrochlorothiazide- amlodipine

Amiloride-hydrochlorothiazide

Amlodipine-hydrochlorothiazide- olmesartan

Amlodipine-hydrochlorothiazide- valsartan

Atenolol-chlorthalidone Azilsartan-chlorthalidone Benazepril-hydrochlorothiazide Bendroflumethiazide-nadolol Bisoprolol-hydrochlorothiazide Candesartan-hydrochlorothiazide Captopril-hydrochlorothiazide Chlorthalidone-clonidine

Enalapril-hydrochlorothiazide

Eprosartan-hydrochlorothiazide Fosinopril-hydrochlorothiazide Hydrochlorothiazide-irbesartan Hydrochlorothiazide-lisinopril Hydrochlorothiazide-losartan Hydrochlorothiazide-methyldopa Hydrochlorothiazide-metoprolol Hydrochlorothiazide-moexipril Hydrochlorothiazide-olmesartan Hydrochlorothiazide-propranolol Hydrochlorothiazide-quinapril Hydrochlorothiazide-

spironolactone

Hydrochlorothiazide-telmisartan Hydrochlorothiazide-triamterene Hydrochlorothiazide-valsartan

Loop diuretics

Bumetanide

Ethacrynic acid

Furosemide

Torsemide

Potassium- sparing diuretics

Amiloride

Eplerenone

Spironolactone

Triamterene

Thiazide diuretics

Chlorothiazide Chlorthalidone Hydrochlorothiazide

Indapamide Methyclothiazide Metolazone

Numerator

At least one serum potassium and a serum creatinine therapeutic monitoring test in the measurement period. Any of the following during the measurement period meet criteria:

•A lab panel test (Lab Panel Value Set).

•A serum potassium test (Serum Potassium Value Set) and a serum creatinine test

(Serum Creatinine Value Set).

The tests do not need to occur on the same service date, only within the measurement period.

Exclusions (optional)

Exclude individuals from each eligible population rate who had an inpatient (acute or non-acute) claim/ encounter during the measurement period.

1.4.1 - Abnormal results follow-up: % of abnormal results with appropriate and timely documentation and follow-upI. BACKGROUNDMeasure Title: Abnormal Results Follow-UpMeasure Description

% of abnormal ambulatory care results with appropriate and timely documentation and follow-up for Potassium, INR, and Mammograms.

Project(s)

1.4 Patient Safety in the Ambulatory Care Setting

Measure Steward Entity(/ies), Organization

Alameda Health System

II. REPORTING

Measure Description:

This measure assesses the percentage of patients 18 years of age and older who received any of each of the following ambulatory care tests and follow-up during the measurement period: At least 180 treatment days of ACE/ARB or Diuretic, at least one potassium monitoring event, and follow-up appropriate to the result; warfarin therapy for at least 56 days, at least one INR monitoring test during each 56-day interval with active warfarin therapy, and follow-up appropriate to the result; and/or was assessed for breast cancer with a mammogram and received follow-up appropriate to the resultant BIRADs assessment.

The metric will be reported as 3 individual rates.

Potassium: Appropriate Monitoring and Follow-up

This measure assesses the percentage of ambulatory care serum potassium tests performed on patients 18 years of age and older who received at least 180 treatment days of ACE, ARB or Diuretic therapy during the measurement year, at least one potassium monitoring event for the therapeutic agent in the measurement year, and follow-up appropriate to the results of that potassium monitoring event.

Numerator Statement:

This measure is calculated and reported as only one total rate.

Measure Numerator

Number of denominator serum Potassium tests that have had appropriate follow-up, as per the following:

· Potassium (K) 3.5 – 5.1 Normal range, no lab follow-up

· Potassium ≥3 and <3.5 Follow up lab in 4 weeks

· Potassium ≥5.2 and < 6 Follow up lab in 10 days

· Potassium <3 or ≥6 Documented as a critical lab value and that the ordering clinician (or responsible delegate) has been informed within 24 hours

Numerator Code/s (CPT, ICD10, other)

· Follow-up

· Date of Follow-up

· Date and time of documentation that ordering clinician has been informed

Denominator Statement:

The number of serum potassium tests completed in the ambulatory setting during the measurement year in PRIME Eligible Population patients age 18 and older, as of the end of the measurement period, who are on selected persistent medications (ACE Inhibitors/ARB or Diuretics) for at least 180 days.

Denominator Codes: (CPT, ICD10, other)

· Patient ID

· Data of prescriptions

· Lab code

· Date of Lab result

· Lab Result

· Medications (NDC code sets): See Abnormal Result Spreadsheet

Exclusion/s

Tests ordered from the emergency department or inpatient setting. Tests ordered from urgent care settings that are located within an emergency department may also be excluded.

Reporting Business Logic

[Pending]

Definitions as applicable

Ambulatory care tests/Ambulatory setting

Any of the referenced tests ordered from any primary care, specialty care or urgent care setting. Tests may be ordered by primary or specialty care providers.

Other Notes as applicable

Potassium ordering from Annual Monitoring for Patients on Persistent Medications.

If follow-up serum Potassium tests are performed in the ambulatory setting and are also outside the normal range, they too will be will be included in the denominator, with subsequent follow-up serum Potassium tests being included in the numerator.

Measurement Period as applicable

DY 11: Final End of Year:

· July 1, 2015 through June 30, 2016

DY 12-DY 15:

· Interim Mid-Year: January 1, 20xx through December 31, 20xx

· Final End of Year: July 1, 20xx through June 30, 20xx

INR: Appropriate Monitoring and Follow-upMeasure Numerator

Number of denominator INR's that have had appropriate follow-up as per the following:

· INR < 2 follow up with a new lab in 4 weeks

· INR 2-3.5No lab follow-up

· INR > 3.5 and <4.9 follow up with a new lab in 10 days

· INR >4.9 Documented as a critical lab value and that the ordering clinician (or responsible delegate) has been informed within 24 hours


· Follow-up


· Date and time of documentation that ordering clinician has been informed

Measure Denominator

The number of INR's completed in the ambulatory setting during the measurement year for individuals in the Target Population, at least 18 years of age as of the beginning of the measurement period with warfarin therapy for at least 56 days during the measurement period and who have at least one INR monitoring test during each 56-day interval with active warfarin therapy. Please Refer to Specs for Metric NQF 0555 for all specifications necessary to calculate the denominator for the INR portion of the Abnormal Results Follow-up metric.

Denominator Code/s (CPT, ICD10, other)

· Date and time of index INR

· See NQF 0555 Please Refer to Specs for Metric NQF 0555

Exclusion/s

Individuals monitoring INR at home. Individuals who are in long-term care during the measurement period.

INR tests ordered from the emergency department or inpatient setting. INR tests ordered from urgent care settings that are located within an emergency department may also be excluded.


Definitions as applicable

Ambulatory care tests/Ambulatory setting

Any of the referenced tests ordered from any primary care, specialty care or urgent care setting. Tests may be ordered by primary or specialty care providers.


If follow-up INR’s are performed in the ambulatory setting and are also outside the normal range, they too will be will be included in the denominator, with subsequent follow-up INR’s being included in the numerator.



· July 1, 2015 through June 30, 2016

DY 12-DY 15:

· Interim Mid-Year: January 1, 20xx through December 31, 20xx


BIRADs Follow-upMeasure Numerator

Number of denominator mammograms that received appropriate follow-up based on the results of the BIRAD assessment, as per the following:

· BIRADS = 0 Recall for additional images or comparison with prior mammograms within 30 days of index mammogram

· BIRADS = 1 or 2 Routine follow-up

· BIRADS = 3 6 month follow up study


· Follow-up


Measure Denominator

Number of index mammograms performed PRIME Eligible Population individuals during the measurement period as defined below under “Measurement Period as applicable”

Denominator Code/s (CPT, ICD10, other)

· Patient ID

· Patient DOB

· Date of Mammogram result

· Mammogram BIRADS Assessment score

Exclusion/s

Any Mammogram with a result of BIRADS 4 or 5.

Mammograms ordered from the emergency department or inpatient setting. Mammograms ordered from urgent care settings that are located within an emergency department may also be excluded.


None

Definitions as applicable Ambulatory care tests/Ambulatory setting

Any of mammograms ordered from any primary care, specialty care or urgent care setting. Tests may be ordered by primary or specialty care providers.


None



· BIRADS = 0 (30 day follow-up):

· Index Mammogram from July 1, 2015 to May 31, 2016

· Recall for additional images or comparison with prior mammograms from July 1, 2015 through June 30, 2016

· BIRADS = 1 or 2 (1-2 year follow-up):

· Index Mammogram from July 1, 2013 to June 30, 2014

· Routine follow-up mammogram from July 1, 2015 to June 30, 2016

· BIRADS = 3 (6 month follow-up):

· Index Mammogram from January 1, 2015 to December 31, 2015

· Follow-up mammogram from July 1, 2015 to June 30, 2016

DY 12:

· Interim Mid-Year:



· Recall for additional images or comparison with prior mammograms from January 1, 2016 through December 31, 2016


· Index Mammogram from January 1, 2014 through December 31, 2014

· Routine follow-up mammogram from January 1, 2016 to December 31, 2016



· Follow-up mammogram from January 1, 2016 to December 31, 2016











DY 13:











· Final End of Year:










DY 14:










· Follow-up mammogram from January 1, 2018 to December, 2018











DY 15:





















III. RATIONALERationale for MeasureScientific Acceptability

1.4.3 - NQF 0555: INR Monitoring for Individuals on Warfarin

Brief Description

Percentage of individuals in the Project 1.4 Target Population at least 18 years of age as of the beginning of the measurement period with at least 56 days of warfarin therapy who receive an International Normalized Ratio (INR) test during each 56-day interval with warfarin

Numerator Statement: The number of individuals in the denominator who have at least one INR monitoring test during each 56-day interval with active warfarin therapy

Time Period for Data: The time period of the data is defined as any time during the measurement period (12 consecutive months).

Numerator Details: Individuals in the denominator who have at least one INR test performed during each 56-day interval with warfarin therapy, or 100% INR monitoring compliance, will be counted in the numerator. Each 56-day interval with an INR testis used to calculate the INR compliance rate for the individual. An interval with a hospitalization of more than 48 hours is considered an interval with an INR test.

INR Test: Prothrombin time, CPT 85610

“Warfarin usage” or “warfarin therapy” is determined by the start date of the first prescription for warfarin up through the start date of the last prescription for warfarin plus the days’ supply from the last claim.

Interval: 56 days

The first day of the first 56-day interval is the start date of the first warfarin prescription, and the last day of the first 56-day interval is the start date of the first warfarin prescription + 55. The subsequent 56-day interval starts on the day after the first 56-day interval and ends 56 days following the first 56-day interval, as long as this end date occurs within the warfarin therapy time frame. This process continues until a calculated 56-day interval end date does not occur within the warfarin therapy time frame. If there are fewer than 56 days of warfarin therapy remaining, those remaining days are not counted in any interval in determining the numerator. Only full 56-day intervals are used for calculating the numerator.

For individuals who died during the measurement year, set warfarin therapy end date to be the death date of the individual

Denominator Details

Project 1.4 Target Population

Active Ingredients by Class

Anticoagulants: warfarin

Note: The active ingredient is limited to oral formulations only.

Denominator Exclusions

Individuals who are monitoring INR at home

Optional Exclusion Criteria

Individuals who are in long-term care (LTC) during the measurement period

Denominator Exclusion Details:

Table 1. HCPCS Codes for INR Monitoring at Home

G0248 - DEMONSTRATE USE HOME INR MON

G0249 - PROVIDE TEST MATS & EQUIP HOME INR

G0250 - MD INR TEST REVIEW INTER MGMT

Stratification Details/Variables S.12.

Depending on the operational use of the measure, measure results may be stratified by:

· State

· Plan

· ACOs*

· Physician Group**

· Age – Divided into six categories: 18-24, 25-44, 45-64, 65-74, 75-84, and 85+ years

· Race/Ethnicity

· Dual Eligibility Status

· New Warfarin User vs. Continuous Warfarin User: “New” users are defined as those individuals with no warfarin prescriptions during the 180 days prior to the first warfarin prescription in the current measurement period.

· Diagnosis Indications for Warfarin: Atrial Fibrillation, Acute Myocardial Infarction, Venous Thromboembolism, Stroke, Mechanical Heart Valve

*ACO attribution methodology is based on where the beneficiary is receiving the plurality of his/her primary care services and subsequently assigned to the participating providers.

**See Calculation Algorithm/Measure Logic S.18 below for physician group attribution methodology used for this measure.

For full measure specification, see NQF 0555 Measure Information Form and Code Table

(*Outstanding for V2.0. Will be updated in future version.Questions or feedback on metrics: complete survey)Page 1 of 9

#9 Abnormal Result

Innovative Metric_Codes.xlsx

ACE-IPRODUCTIDPRODUCTNDCPRODUCTTYPENAMEPROPRIETARYNAMEPROPRIETARYNAMESUFFIXNONPROPRIETARYNAMEDOSAGEFORMNAMEROUTENAMESTARTMARKETINGDATEENDMARKETINGDATEMARKETINGCATEGORYNAMEAPPLICATIONNUMBERLABELERNAMESUBSTANCENAMEACTIVE_NUMERATOR_STRENGTHACTIVE_INGRED_UNITPHARM_CLASSESDEASCHEDULE0006-0019_de13746c-75ab-4326-9f82-ae37a19b34850006-0019HUMAN PRESCRIPTION DRUGPRINIVILlisinoprilTABLETORAL19871229NDANDA019558Merck Sharp & Dohme Corp.LISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0006-0106_de13746c-75ab-4326-9f82-ae37a19b34850006-0106HUMAN PRESCRIPTION DRUGPRINIVILlisinoprilTABLETORAL19871229NDANDA019558Merck Sharp & Dohme Corp.LISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0006-0207_de13746c-75ab-4326-9f82-ae37a19b34850006-0207HUMAN PRESCRIPTION DRUGPRINIVILlisinoprilTABLETORAL19871229NDANDA019558Merck Sharp & Dohme Corp.LISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0054-0106_7ef5e23b-e5a0-441a-85d4-4b50a060ec9f0054-0106HUMAN PRESCRIPTION DRUGRamiprilRamiprilCAPSULEORAL20080618ANDAANDA077900Roxane Laboratories, IncRAMIPRIL1.25mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0054-0107_7ef5e23b-e5a0-441a-85d4-4b50a060ec9f0054-0107HUMAN PRESCRIPTION DRUGRamiprilRamiprilCAPSULEORAL20080618ANDAANDA077900Roxane Laboratories, IncRAMIPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0054-0108_7ef5e23b-e5a0-441a-85d4-4b50a060ec9f0054-0108HUMAN PRESCRIPTION DRUGRamiprilRamiprilCAPSULEORAL20080618ANDAANDA077900Roxane Laboratories, IncRAMIPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0054-0109_7ef5e23b-e5a0-441a-85d4-4b50a060ec9f0054-0109HUMAN PRESCRIPTION DRUGRamiprilRamiprilCAPSULEORAL20080618ANDAANDA077900Roxane Laboratories, IncRAMIPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0054-0110_dc50c8a3-ab29-49d5-b71b-67afe91639e20054-0110HUMAN PRESCRIPTION DRUGPerindopril ErbuminePerindopril ErbumineTABLETORAL20091110ANDAANDA090072Roxane Laboratories, Inc.PERINDOPRIL ERBUMINE2mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0054-0111_dc50c8a3-ab29-49d5-b71b-67afe91639e20054-0111HUMAN PRESCRIPTION DRUGPerindopril ErbuminePerindopril ErbumineTABLETORAL20091110ANDAANDA090072Roxane Laboratories, Inc.PERINDOPRIL ERBUMINE4mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0054-0112_dc50c8a3-ab29-49d5-b71b-67afe91639e20054-0112HUMAN PRESCRIPTION DRUGPerindopril ErbuminePerindopril ErbumineTABLETORAL20091110ANDAANDA090072Roxane Laboratories, Inc.PERINDOPRIL ERBUMINE8mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0071-0220_c1959c67-9f77-4421-94bd-add5cbe528f10071-0220HUMAN PRESCRIPTION DRUGACCURETICquinapril hydrochloride and hydrochlorothiazideTABLET, FILM COATEDORAL19991228NDANDA020125Parke-Davis Div of Pfizer IncQUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0071-0222_c1959c67-9f77-4421-94bd-add5cbe528f10071-0222HUMAN PRESCRIPTION DRUGACCURETICquinapril hydrochloride and hydrochlorothiazideTABLET, FILM COATEDORAL19991228NDANDA020125Parke-Davis Div of Pfizer IncQUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0071-0223_c1959c67-9f77-4421-94bd-add5cbe528f10071-0223HUMAN PRESCRIPTION DRUGACCURETICquinapril hydrochloride and hydrochlorothiazideTABLET, FILM COATEDORAL19991228NDANDA020125Parke-Davis Div of Pfizer IncQUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0071-0527_1a25662a-eb93-4ee5-9252-57013b42e4660071-0527HUMAN PRESCRIPTION DRUGAccuprilquinapril hydrochlorideTABLET, FILM COATEDORAL19911119NDANDA019885Parke-Davis Div of Pfizer IncQUINAPRIL HYDROCHLORIDE5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0071-0530_1a25662a-eb93-4ee5-9252-57013b42e4660071-0530HUMAN PRESCRIPTION DRUGAccuprilquinapril hydrochlorideTABLET, FILM COATEDORAL19911119NDANDA019885Parke-Davis Div of Pfizer IncQUINAPRIL HYDROCHLORIDE10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0071-0532_1a25662a-eb93-4ee5-9252-57013b42e4660071-0532HUMAN PRESCRIPTION DRUGAccuprilquinapril hydrochlorideTABLET, FILM COATEDORAL19911119NDANDA019885Parke-Davis Div of Pfizer IncQUINAPRIL HYDROCHLORIDE20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0071-0535_1a25662a-eb93-4ee5-9252-57013b42e4660071-0535HUMAN PRESCRIPTION DRUGAccuprilquinapril hydrochlorideTABLET, FILM COATEDORAL19911119NDANDA019885Parke-Davis Div of Pfizer IncQUINAPRIL HYDROCHLORIDE40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0074-2278_1a25b900-57e1-87c3-6bd9-3832059650590074-2278HUMAN PRESCRIPTION DRUGMavikTrandolaprilTABLETORAL19960426NDANDA020528AbbVie Inc.TRANDOLAPRIL1mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0074-2279_1a25b900-57e1-87c3-6bd9-3832059650590074-2279HUMAN PRESCRIPTION DRUGMavikTrandolaprilTABLETORAL19960426NDANDA020528AbbVie Inc.TRANDOLAPRIL2mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0074-2280_1a25b900-57e1-87c3-6bd9-3832059650590074-2280HUMAN PRESCRIPTION DRUGMavikTrandolaprilTABLETORAL19960426NDANDA020528AbbVie Inc.TRANDOLAPRIL4mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0074-3287_836a02e2-731d-1198-f739-3e3ff66042950074-3287HUMAN PRESCRIPTION DRUGTarkaTrandolapril and Verapamil HydrochlorideTABLET, FILM COATED, EXTENDED RELEASEORAL19961022NDANDA020591AbbVie Inc.TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE2; 180mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker [EPC]0074-3288_836a02e2-731d-1198-f739-3e3ff66042950074-3288HUMAN PRESCRIPTION DRUGTarkaTrandolapril and Verapamil HydrochlorideTABLET, FILM COATED, EXTENDED RELEASEORAL19961022NDANDA020591AbbVie Inc.TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE1; 240mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker [EPC]0074-3289_836a02e2-731d-1198-f739-3e3ff66042950074-3289HUMAN PRESCRIPTION DRUGTarkaTrandolapril and Verapamil HydrochlorideTABLET, FILM COATED, EXTENDED RELEASEORAL19961022NDANDA020591AbbVie Inc.TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE2; 240mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker [EPC]0074-3290_836a02e2-731d-1198-f739-3e3ff66042950074-3290HUMAN PRESCRIPTION DRUGTarkaTrandolapril and Verapamil HydrochlorideTABLET, FILM COATED, EXTENDED RELEASEORAL19961022NDANDA020591AbbVie Inc.TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE4; 240mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker [EPC]0078-0364_556066cf-974c-4020-94f6-d2b7410c746d0078-0364HUMAN PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE10; 20mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0078-0379_556066cf-974c-4020-94f6-d2b7410c746d0078-0379HUMAN PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE10; 40mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0078-0384_556066cf-974c-4020-94f6-d2b7410c746d0078-0384HUMAN PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE5; 40mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0078-0404_556066cf-974c-4020-94f6-d2b7410c746d0078-0404HUMAN PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE2.5; 10mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0078-0405_556066cf-974c-4020-94f6-d2b7410c746d0078-0405HUMAN PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE5; 10mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0078-0406_556066cf-974c-4020-94f6-d2b7410c746d0078-0406HUMAN PRESCRIPTION DRUGLotrelamlodipine besylate and benazepril hydrochlorideCAPSULEORAL19950303NDANDA020364Novartis Pharmaceuticals CorporationAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE5; 20mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0091-3707_2c711a79-fc80-331d-e054-00144ff88e880091-3707HUMAN PRESCRIPTION DRUGUnivascmoexipril hydrochlorideTABLET, FILM COATEDORAL19950715NDANDA020312UCB, Inc.MOEXIPRIL HYDROCHLORIDE7.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-0017_17a7d6c6-89ea-4293-9d90-a92e7c6f49560093-0017HUMAN PRESCRIPTION DRUGMoexipril HydrochlorideMoexipril HydrochlorideTABLET, FILM COATEDORAL20030508ANDAANDA076204Teva Pharmaceuticals USA IncMOEXIPRIL HYDROCHLORIDE7.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-0026_19803835-979a-436c-8a59-019bd9f1cf990093-0026HUMAN PRESCRIPTION DRUGEnalapril MaleateEnalapril MaleateTABLETORAL20000823ANDAANDA075479Teva Pharmaceuticals USA IncENALAPRIL MALEATE2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-0027_19803835-979a-436c-8a59-019bd9f1cf990093-0027HUMAN PRESCRIPTION DRUGEnalapril MaleateEnalapril MaleateTABLETORAL20000823ANDAANDA075479Teva Pharmaceuticals USA IncENALAPRIL MALEATE5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-0028_19803835-979a-436c-8a59-019bd9f1cf990093-0028HUMAN PRESCRIPTION DRUGEnalapril MaleateEnalapril MaleateTABLETORAL20000823ANDAANDA075479Teva Pharmaceuticals USA IncENALAPRIL MALEATE10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-0029_19803835-979a-436c-8a59-019bd9f1cf990093-0029HUMAN PRESCRIPTION DRUGEnalapril MaleateEnalapril MaleateTABLETORAL20000823ANDAANDA075479Teva Pharmaceuticals USA IncENALAPRIL MALEATE20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-1052_775cd8ad-6c18-4ed4-a84f-4213263b7dbd0093-1052HUMAN PRESCRIPTION DRUGEnalapril Maleate and HydrochlorothiazideEnalapril Maleate and HydrochlorothiazideTABLETORAL2001091920160430ANDAANDA075727Teva Pharmaceuticals USA IncENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE10; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0093-5124_d61feec5-cf0f-42ca-8f2e-85b3cb95de420093-5124HUMAN PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril HydrochlorideTABLET, COATEDORAL20040211ANDAANDA076211Teva Pharmaceuticals USA IncBENAZEPRIL HYDROCHLORIDE5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-5125_d61feec5-cf0f-42ca-8f2e-85b3cb95de420093-5125HUMAN PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril HydrochlorideTABLET, COATEDORAL20040211ANDAANDA076211Teva Pharmaceuticals USA IncBENAZEPRIL HYDROCHLORIDE10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-5126_d61feec5-cf0f-42ca-8f2e-85b3cb95de420093-5126HUMAN PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril HydrochlorideTABLET, COATEDORAL20040211ANDAANDA076211Teva Pharmaceuticals USA IncBENAZEPRIL HYDROCHLORIDE20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-5127_d61feec5-cf0f-42ca-8f2e-85b3cb95de420093-5127HUMAN PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril HydrochlorideTABLET, COATEDORAL20040211ANDAANDA076211Teva Pharmaceuticals USA IncBENAZEPRIL HYDROCHLORIDE40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-5150_17a7d6c6-89ea-4293-9d90-a92e7c6f49560093-5150HUMAN PRESCRIPTION DRUGMoexipril HydrochlorideMoexipril HydrochlorideTABLET, FILM COATEDORAL20030508ANDAANDA076204Teva Pharmaceuticals USA IncMOEXIPRIL HYDROCHLORIDE15mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-5213_7176f8ee-94b8-4bc0-bb0e-e659a9ff27350093-5213HUMAN PRESCRIPTION DRUGMoexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride and HydrochlorothiazideTABLET, FILM COATEDORAL20070307ANDAANDA076980Teva Pharmaceuticals USA IncMOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE7.5; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0093-5214_7176f8ee-94b8-4bc0-bb0e-e659a9ff27350093-5214HUMAN PRESCRIPTION DRUGMoexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride and HydrochlorothiazideTABLET, FILM COATEDORAL20070307ANDAANDA076980Teva Pharmaceuticals USA IncMOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE15; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0093-5215_7176f8ee-94b8-4bc0-bb0e-e659a9ff27350093-5215HUMAN PRESCRIPTION DRUGMoexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride and HydrochlorothiazideTABLET, FILM COATEDORAL20070307ANDAANDA076980Teva Pharmaceuticals USA IncMOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE15; 25mg/1; mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7222_a733b7d3-d690-42ab-aa97-eadfee03e9760093-7222HUMAN PRESCRIPTION DRUGFosinopril SodiumFosinopril SodiumTABLETORAL20031201ANDAANDA076139Teva Pharmaceuticals USA IncFOSINOPRIL SODIUM10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7223_a733b7d3-d690-42ab-aa97-eadfee03e9760093-7223HUMAN PRESCRIPTION DRUGFosinopril SodiumFosinopril SodiumTABLETORAL20031201ANDAANDA076139Teva Pharmaceuticals USA IncFOSINOPRIL SODIUM20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7224_a733b7d3-d690-42ab-aa97-eadfee03e9760093-7224HUMAN PRESCRIPTION DRUGFosinopril SodiumFosinopril SodiumTABLETORAL20031201ANDAANDA076139Teva Pharmaceuticals USA IncFOSINOPRIL SODIUM40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7325_89a9bdcd-51ba-4ad1-b417-7819b1d1bafa0093-7325HUMAN PRESCRIPTION DRUGTrandolaprilTrandolaprilTABLETORAL2007020720160229ANDAANDA077489Teva Pharmaceuticals USA IncTRANDOLAPRIL1mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7326_89a9bdcd-51ba-4ad1-b417-7819b1d1bafa0093-7326HUMAN PRESCRIPTION DRUGTrandolaprilTrandolaprilTABLETORAL2007020720160331ANDAANDA077489Teva Pharmaceuticals USA IncTRANDOLAPRIL2mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7327_89a9bdcd-51ba-4ad1-b417-7819b1d1bafa0093-7327HUMAN PRESCRIPTION DRUGTrandolaprilTrandolaprilTABLETORAL2007020720160831ANDAANDA077489Teva Pharmaceuticals USA IncTRANDOLAPRIL4mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7370_a01949e8-8e46-44d2-94db-79863663a25d0093-7370HUMAN PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine and Benazepril HydrochlorideCAPSULEORAL20070518ANDAANDA077179Teva Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE2.5; 10mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-7371_a01949e8-8e46-44d2-94db-79863663a25d0093-7371HUMAN PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine and Benazepril HydrochlorideCAPSULEORAL20070518ANDAANDA077179Teva Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE5; 10mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-7372_a01949e8-8e46-44d2-94db-79863663a25d0093-7372HUMAN PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine and Benazepril HydrochlorideCAPSULEORAL20070518ANDAANDA077179Teva Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE5; 20mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-7373_a01949e8-8e46-44d2-94db-79863663a25d0093-7373HUMAN PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine and Benazepril HydrochlorideCAPSULEORAL20070518ANDAANDA077179Teva Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE10; 20mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-7436_3bc351c7-2578-485c-8f80-bef09a288d410093-7436HUMAN PRESCRIPTION DRUGRamiprilRamiprilCAPSULEORAL2008062420160731ANDAANDA077470Teva Pharmaceuticals USA IncRAMIPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7437_3bc351c7-2578-485c-8f80-bef09a288d410093-7437HUMAN PRESCRIPTION DRUGRamiprilRamiprilCAPSULEORAL2008062420160331ANDAANDA077470Teva Pharmaceuticals USA IncRAMIPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7438_3bc351c7-2578-485c-8f80-bef09a288d410093-7438HUMAN PRESCRIPTION DRUGRamiprilRamiprilCAPSULEORAL2008062420160331ANDAANDA077470Teva Pharmaceuticals USA IncRAMIPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0093-7670_a01949e8-8e46-44d2-94db-79863663a25d0093-7670HUMAN PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine and Benazepril HydrochlorideCAPSULEORAL20110720ANDAANDA077179Teva Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE5; 40mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0093-7671_a01949e8-8e46-44d2-94db-79863663a25d0093-7671HUMAN PRESCRIPTION DRUGAmlodipine and Benazepril HydrochlorideAmlodipine and Benazepril HydrochlorideCAPSULEORAL20110720ANDAANDA077179Teva Pharmaceuticals USA IncAMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE10; 40mg/1; mg/1Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0143-1171_0eb938d3-4faa-4bd9-96bc-ca8b95a80e390143-1171HUMAN PRESCRIPTION DRUGCaptoprilCaptoprilTABLETORAL19960213ANDAANDA074505West-Ward Pharmaceuticals CorpCAPTOPRIL12.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1172_0eb938d3-4faa-4bd9-96bc-ca8b95a80e390143-1172HUMAN PRESCRIPTION DRUGCaptoprilCaptoprilTABLETORAL19960213ANDAANDA074505West-Ward Pharmaceuticals CorpCAPTOPRIL25mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1173_0eb938d3-4faa-4bd9-96bc-ca8b95a80e390143-1173HUMAN PRESCRIPTION DRUGCaptoprilCaptoprilTABLETORAL19960213ANDAANDA074505West-Ward Pharmaceuticals CorpCAPTOPRIL50mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1174_0eb938d3-4faa-4bd9-96bc-ca8b95a80e390143-1174HUMAN PRESCRIPTION DRUGCaptoprilCaptoprilTABLETORAL19960213ANDAANDA074505West-Ward Pharmaceuticals CorpCAPTOPRIL100mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1262_ebb57b71-8e07-4997-b865-5584555470be0143-1262HUMAN PRESCRIPTION DRUGLisinopril with HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020708ANDAANDA076265West-Ward Pharmaceuticals CorpHYDROCHLOROTHIAZIDE; LISINOPRIL12.5; 10mg/1; mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1263_ebb57b71-8e07-4997-b865-5584555470be0143-1263HUMAN PRESCRIPTION DRUGLisinopril with HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020708ANDAANDA076265West-Ward Pharmaceuticals CorpHYDROCHLOROTHIAZIDE; LISINOPRIL12.5; 20mg/1; mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1264_ebb57b71-8e07-4997-b865-5584555470be0143-1264HUMAN PRESCRIPTION DRUGLisinopril with HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020708ANDAANDA076265West-Ward Pharmaceuticals CorpHYDROCHLOROTHIAZIDE; LISINOPRIL25; 20mg/1; mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1266_2696dc8a-b5e1-48cf-8118-976b92f0433d0143-1266HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA076063West-Ward Pharmaceuticals CorpLISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1267_2696dc8a-b5e1-48cf-8118-976b92f0433d0143-1267HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA076063West-Ward Pharmaceuticals CorpLISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1268_2696dc8a-b5e1-48cf-8118-976b92f0433d0143-1268HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA076063West-Ward Pharmaceuticals CorpLISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-1270_2696dc8a-b5e1-48cf-8118-976b92f0433d0143-1270HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA076063West-Ward Pharmaceuticals CorpLISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-9713_662060b3-7bd7-436e-8b24-b0b99ed2b9060143-9713HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20130213ANDAANDA076063West-Ward Pharmaceuticals CorpLISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-9714_662060b3-7bd7-436e-8b24-b0b99ed2b9060143-9714HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20130213ANDAANDA076063West-Ward Pharmaceuticals CorpLISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0143-9715_662060b3-7bd7-436e-8b24-b0b99ed2b9060143-9715HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20130213ANDAANDA076063West-Ward Pharmaceuticals CorpLISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0172-3757_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3757HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX Pharmaceuticals, Inc.LISINOPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0172-3758_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3758HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX Pharmaceuticals, Inc.LISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0172-3759_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3759HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX Pharmaceuticals, Inc.LISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0172-3760_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3760HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX Pharmaceuticals, Inc.LISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0172-3761_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3761HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX Pharmaceuticals, Inc.LISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0172-3762_b50132eb-d135-40d4-9d8b-7527952ef8df0172-3762HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20020701ANDAANDA075752IVAX Pharmaceuticals, Inc.LISINOPRIL30mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0172-5032_77ab08d3-f07f-4c75-b70a-f4c2c7c8645e0172-5032HUMAN PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020701ANDAANDA075776IVAX Pharmaceuticals, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0172-5033_77ab08d3-f07f-4c75-b70a-f4c2c7c8645e0172-5033HUMAN PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020701ANDAANDA075776IVAX Pharmaceuticals, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0172-5034_77ab08d3-f07f-4c75-b70a-f4c2c7c8645e0172-5034HUMAN PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020701ANDAANDA075776IVAX Pharmaceuticals, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0179-0135_10055ce4-847f-456b-949b-b8697a318d9f0179-0135HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20130805ANDAANDA077321KAISER FOUNDATION HOSPITALSLISINOPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0179-1984_10055ce4-847f-456b-949b-b8697a318d9f0179-1984HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20081103ANDAANDA077321KAISER FOUNDATION HOSPITALSLISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0179-1985_10055ce4-847f-456b-949b-b8697a318d9f0179-1985HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20081103ANDAANDA077321KAISER FOUNDATION HOSPITALSLISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0179-1988_10055ce4-847f-456b-949b-b8697a318d9f0179-1988HUMAN PRESCRIPTION DRUGLisinoprilLisinoprilTABLETORAL20081103ANDAANDA077321KAISER FOUNDATION HOSPITALSLISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0025_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0025HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL2002070120170930ANDAANDA075994Eon Labs, Inc.LISINOPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0041_100a257a-261b-411e-8197-dac277df9d530185-0041HUMAN PRESCRIPTION DRUGFosinopril SodiumFosinopril SodiumTABLETORAL20040423ANDAANDA076483Eon Labs, Inc.FOSINOPRIL SODIUM10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0042_100a257a-261b-411e-8197-dac277df9d530185-0042HUMAN PRESCRIPTION DRUGFosinopril SodiumFosinopril SodiumTABLETORAL20040423ANDAANDA076483Eon Labs, Inc.FOSINOPRIL SODIUM20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0047_100a257a-261b-411e-8197-dac277df9d530185-0047HUMAN PRESCRIPTION DRUGFosinopril SodiumFosinopril SodiumTABLETORAL20040423ANDAANDA076483Eon Labs, Inc.FOSINOPRIL SODIUM40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0053_937c8aa3-b2bf-438a-996f-53d2e455cbc30185-0053HUMAN PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril HydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076402Eon Labs, Inc.BENAZEPRIL HYDROCHLORIDE10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0185-0101_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0101HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL2002070120171130ANDAANDA075994Eon Labs, Inc.LISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0102_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0102HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL2002070120171231ANDAANDA075994Eon Labs, Inc.LISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0103_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0103HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL2002070120171130ANDAANDA075994Eon Labs, Inc.LISINOPRIL30mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0104_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0104HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL2002070120171130ANDAANDA075994Eon Labs, Inc.LISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0152_c057cfdf-3bfe-419f-9aeb-bf266ac4376f0185-0152HUMAN PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020702ANDAANDA076262Eon Labs, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0185-0173_c057cfdf-3bfe-419f-9aeb-bf266ac4376f0185-0173HUMAN PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020701ANDAANDA076262Eon Labs, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0185-0211_1f4a8d87-5394-4a23-b951-19f708af13670185-0211HUMAN PRESCRIPTION DRUGBenazepril Hydrochloride and HydrochlorothiazideBenazepril Hydrochloride and HydrochlorothiazideTABLET, FILM COATEDORAL20040211ANDAANDA076631Eon Labs, Inc.BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0185-0236_1f4a8d87-5394-4a23-b951-19f708af13670185-0236HUMAN PRESCRIPTION DRUGBenazepril Hydrochloride and HydrochlorothiazideBenazepril Hydrochloride and HydrochlorothiazideTABLET, FILM COATEDORAL20150317ANDAANDA076631Eon Labs, Inc.BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE5; 6.25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0185-0277_1f4a8d87-5394-4a23-b951-19f708af13670185-0277HUMAN PRESCRIPTION DRUGBenazepril Hydrochloride and HydrochlorothiazideBenazepril Hydrochloride and HydrochlorothiazideTABLET, FILM COATEDORAL20040211ANDAANDA076631Eon Labs, Inc.BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0185-0325_1f4a8d87-5394-4a23-b951-19f708af13670185-0325HUMAN PRESCRIPTION DRUGBenazepril Hydrochloride and HydrochlorothiazideBenazepril Hydrochloride and HydrochlorothiazideTABLET, FILM COATEDORAL20140404ANDAANDA076631Eon Labs, Inc.BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0185-0341_114dc847-8ad5-47c2-ad22-6efd5b73f9a60185-0341HUMAN PRESCRIPTION DRUGFosinopril Sodium and HydrochlorothiazideFosinopril Sodium and HydrochlorothiazideTABLETORAL20050928ANDAANDA076961Eon Labs, Inc.FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0185-0342_114dc847-8ad5-47c2-ad22-6efd5b73f9a60185-0342HUMAN PRESCRIPTION DRUGFosinopril Sodium and HydrochlorothiazideFosinopril Sodium and HydrochlorothiazideTABLETORAL20050928ANDAANDA076961Eon Labs, Inc.FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0185-0505_937c8aa3-b2bf-438a-996f-53d2e455cbc30185-0505HUMAN PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril HydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076402Eon Labs, Inc.BENAZEPRIL HYDROCHLORIDE5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0185-0602_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0602HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL20151221ANDAANDA075994Eon Labs, Inc.LISINOPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0610_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0610HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL20150521ANDAANDA075994Eon Labs, Inc.LISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0620_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0620HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL20150523ANDAANDA075994Eon Labs, Inc.LISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0630_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0630HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL20150819ANDAANDA075994Eon Labs, Inc.LISINOPRIL30mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0640_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-0640HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL20150609ANDAANDA075994Eon Labs, Inc.LISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-0820_937c8aa3-b2bf-438a-996f-53d2e455cbc30185-0820HUMAN PRESCRIPTION DRUGBenazepril HydrochlorideBenazepril HydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076402Eon Labs, Inc.BENAZEPRIL HYDROCHLORIDE20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0185-5400_00a1e9cd-8de5-4d73-95ae-1ea6c78fafc00185-5400HUMAN PRESCRIPTION DRUGlisinoprillisinoprilTABLETORAL2002070120171130ANDAANDA075994Eon Labs, Inc.LISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0185-7100_c057cfdf-3bfe-419f-9aeb-bf266ac4376f0185-7100HUMAN PRESCRIPTION DRUGLisinopril and HydrochlorothiazideLisinopril and HydrochlorothiazideTABLETORAL20020701ANDAANDA076262Eon Labs, Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0187-0140_842ca03b-e32e-4abe-8bbd-13eb94eb62740187-0140HUMAN PRESCRIPTION DRUGVasotecEnalapril MaleateTABLETORAL19880726NDANDA018998Valeant Pharmaceuticals North America LLCENALAPRIL MALEATE2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0187-0141_842ca03b-e32e-4abe-8bbd-13eb94eb62740187-0141HUMAN PRESCRIPTION DRUGVasotecEnalapril MaleateTABLETORAL19851224NDANDA018998Valeant Pharmaceuticals North America LLCENALAPRIL MALEATE5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0187-0142_842ca03b-e32e-4abe-8bbd-13eb94eb62740187-0142HUMAN PRESCRIPTION DRUGVasotecEnalapril MaleateTABLETORAL19851224NDANDA018998Valeant Pharmaceuticals North America LLCENALAPRIL MALEATE10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0187-0143_842ca03b-e32e-4abe-8bbd-13eb94eb62740187-0143HUMAN PRESCRIPTION DRUGVasotecEnalapril MaleateTABLETORAL19851224NDANDA018998Valeant Pharmaceuticals North America LLCENALAPRIL MALEATE20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0187-0146_0b8c532e-e758-447d-9087-ff0e3bf9df3f0187-0146HUMAN PRESCRIPTION DRUGVasereticenalapril maleate and hydrochlorothiazideTABLETORAL19861031NDANDA019221Valeant Pharmaceuticals North America LLCENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE10; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0310-0130_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0130HUMAN PRESCRIPTION DRUGZESTRILLisinoprilTABLETORAL20091111NDANDA019777AstraZeneca Pharmaceuticals LPLISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0310-0131_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0131HUMAN PRESCRIPTION DRUGZESTRILLisinoprilTABLETORAL20090828NDANDA019777AstraZeneca Pharmaceuticals LPLISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0310-0132_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0132HUMAN PRESCRIPTION DRUGZESTRILLisinoprilTABLETORAL20090513NDANDA019777AstraZeneca Pharmaceuticals LPLISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0310-0133_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0133HUMAN PRESCRIPTION DRUGZESTRILLisinoprilTABLETORAL20100922NDANDA019777AstraZeneca Pharmaceuticals LPLISINOPRIL30mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0310-0134_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0134HUMAN PRESCRIPTION DRUGZESTRILLisinoprilTABLETORAL20100326NDANDA019777AstraZeneca Pharmaceuticals LPLISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0310-0135_65d33be9-0f8c-4651-8955-ff66103f7d1f0310-0135HUMAN PRESCRIPTION DRUGZESTRILLisinoprilTABLETORAL20110902NDANDA019777AstraZeneca Pharmaceuticals LPLISINOPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0310-0141_b0a1ece1-2539-4d34-ac8f-f933b04b0b7f0310-0141HUMAN PRESCRIPTION DRUGZESTORETICLisinopril and HydrochlorothiazideTABLETORAL20100615NDANDA019888AstraZeneca Pharmaceuticals LPLISINOPRIL; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0310-0142_b0a1ece1-2539-4d34-ac8f-f933b04b0b7f0310-0142HUMAN PRESCRIPTION DRUGZESTORETICLisinopril and HydrochlorothiazideTABLETORAL20110509NDANDA019888AstraZeneca Pharmaceuticals LPLISINOPRIL; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0310-0145_b0a1ece1-2539-4d34-ac8f-f933b04b0b7f0310-0145HUMAN PRESCRIPTION DRUGZESTORETICLisinopril and HydrochlorothiazideTABLETORAL20100727NDANDA019888AstraZeneca Pharmaceuticals LPLISINOPRIL; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-0081_3f830175-e2d8-410d-b25a-49e4cc3c97e40378-0081HUMAN PRESCRIPTION DRUGCaptopril and Hydrochlorothiazidecaptopril and hydrochlorothiazideTABLETORAL19971229ANDAANDA074896Mylan Phamaceuticals Inc.CAPTOPRIL; HYDROCHLOROTHIAZIDE25; 15mg/1; mg/1Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-0083_3f830175-e2d8-410d-b25a-49e4cc3c97e40378-0083HUMAN PRESCRIPTION DRUGCaptopril and Hydrochlorothiazidecaptopril and hydrochlorothiazideTABLETORAL19971229ANDAANDA074896Mylan Phamaceuticals Inc.CAPTOPRIL; HYDROCHLOROTHIAZIDE25; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-0084_3f830175-e2d8-410d-b25a-49e4cc3c97e40378-0084HUMAN PRESCRIPTION DRUGCaptopril and Hydrochlorothiazidecaptopril and hydrochlorothiazideTABLETORAL19971229ANDAANDA074896Mylan Phamaceuticals Inc.CAPTOPRIL; HYDROCHLOROTHIAZIDE50; 15mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-0086_3f830175-e2d8-410d-b25a-49e4cc3c97e40378-0086HUMAN PRESCRIPTION DRUGCaptopril and Hydrochlorothiazidecaptopril and hydrochlorothiazideTABLETORAL19971229ANDAANDA074896Mylan Phamaceuticals Inc.CAPTOPRIL; HYDROCHLOROTHIAZIDE50; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-0441_33b1c6ed-b367-4907-b3ae-e1b4911a12c80378-0441HUMAN PRESCRIPTION DRUGBenazepril Hydrochloridebenazepril hydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076430Mylan Pharmaceuticals Inc.BENAZEPRIL HYDROCHLORIDE5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0378-0443_33b1c6ed-b367-4907-b3ae-e1b4911a12c80378-0443HUMAN PRESCRIPTION DRUGBenazepril Hydrochloridebenazepril hydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076430Mylan Pharmaceuticals Inc.BENAZEPRIL HYDROCHLORIDE10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0378-0444_33b1c6ed-b367-4907-b3ae-e1b4911a12c80378-0444HUMAN PRESCRIPTION DRUGBenazepril Hydrochloridebenazepril hydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076430Mylan Pharmaceuticals Inc.BENAZEPRIL HYDROCHLORIDE20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0378-0447_33b1c6ed-b367-4907-b3ae-e1b4911a12c80378-0447HUMAN PRESCRIPTION DRUGBenazepril Hydrochloridebenazepril hydrochlorideTABLET, FILM COATEDORAL20040211ANDAANDA076430Mylan Pharmaceuticals Inc.BENAZEPRIL HYDROCHLORIDE40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0378-0542_b06d635b-9da5-4f4b-8f58-f2850342916f0378-0542HUMAN PRESCRIPTION DRUGQuinapril Hydrochloride and Hydrochlorothiazidequinapril hydrochloride and hydrochlorothiazideTABLET, FILM COATEDORAL20070226ANDAANDA077093Mylan Pharmaceuticals Inc.QUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-0543_b06d635b-9da5-4f4b-8f58-f2850342916f0378-0543HUMAN PRESCRIPTION DRUGQuinapril Hydrochloride and Hydrochlorothiazidequinapril hydrochloride and hydrochlorothiazideTABLET, FILM COATEDORAL20070226ANDAANDA077093Mylan Pharmaceuticals Inc.QUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-0544_b06d635b-9da5-4f4b-8f58-f2850342916f0378-0544HUMAN PRESCRIPTION DRUGQuinapril Hydrochloride and Hydrochlorothiazidequinapril hydrochloride and hydrochlorothiazideTABLET, FILM COATEDORAL20070226ANDAANDA077093Mylan Pharmaceuticals Inc.QUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-0712_77f1b18a-33a2-42bb-acde-c933ad85b8380378-0712HUMAN PRESCRIPTION DRUGEnalapril Maleate and Hydrochlorothiazideenalapril maleate and hydrochlorothiazideTABLETORAL20010919ANDAANDA075624Mylan Pharmaceuticals Inc.ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE5; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-0723_77f1b18a-33a2-42bb-acde-c933ad85b8380378-0723HUMAN PRESCRIPTION DRUGEnalapril Maleate and Hydrochlorothiazideenalapril maleate and hydrochlorothiazideTABLETORAL20010919ANDAANDA075624Mylan Pharmaceuticals Inc.ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE10; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-1012_bc926c3f-d649-40f1-98cf-cea0ad60e6ab0378-1012HUMAN PRESCRIPTION DRUGLisinopril and Hydrochlorothiazidelisinopril and hydrochlorothiazideTABLETORAL20140904ANDAANDA076113Mylan Pharmaceuticals Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE10; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-1051_46369476-5900-4a51-994b-700c3cd89d310378-1051HUMAN PRESCRIPTION DRUGEnalapril Maleateenalapril maleateTABLETORAL20000822ANDAANDA075480Mylan Pharmaceuticals Inc.ENALAPRIL MALEATE2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0378-1052_46369476-5900-4a51-994b-700c3cd89d310378-1052HUMAN PRESCRIPTION DRUGEnalapril MaleateEnalapril MaleateTABLETORAL20000822ANDAANDA075480Mylan Pharmaceuticals Inc.ENALAPRIL MALEATE5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0378-1053_46369476-5900-4a51-994b-700c3cd89d310378-1053HUMAN PRESCRIPTION DRUGEnalapril MaleateEnalapril MaleateTABLETORAL20000822ANDAANDA075480Mylan Pharmaceuticals Inc.ENALAPRIL MALEATE10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0378-1054_46369476-5900-4a51-994b-700c3cd89d310378-1054HUMAN PRESCRIPTION DRUGEnalapril MaleateEnalapril MaleateTABLETORAL20000822ANDAANDA075480Mylan Pharmaceuticals Inc.ENALAPRIL MALEATE20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE]0378-2012_bc926c3f-d649-40f1-98cf-cea0ad60e6ab0378-2012HUMAN PRESCRIPTION DRUGLisinopril and Hydrochlorothiazidelisinopril and hydrochlorothiazideTABLETORAL20140904ANDAANDA076113Mylan Pharmaceuticals Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 12.5mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-2025_bc926c3f-d649-40f1-98cf-cea0ad60e6ab0378-2025HUMAN PRESCRIPTION DRUGLisinopril and Hydrochlorothiazidelisinopril and hydrochlorothiazideTABLETORAL20140904ANDAANDA076113Mylan Pharmaceuticals Inc.LISINOPRIL; HYDROCHLOROTHIAZIDE20; 25mg/1; mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient]0378-2072_9195f48c-59af-471a-8522-1a53845157670378-2072HUMAN PRESCRIPTION DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan Pharmaceuticals Inc.LISINOPRIL2.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-2073_9195f48c-59af-471a-8522-1a53845157670378-2073HUMAN PRESCRIPTION DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan Pharmaceuticals Inc.LISINOPRIL5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-2074_9195f48c-59af-471a-8522-1a53845157670378-2074HUMAN PRESCRIPTION DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan Pharmaceuticals Inc.LISINOPRIL10mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-2075_9195f48c-59af-471a-8522-1a53845157670378-2075HUMAN PRESCRIPTION DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan Pharmaceuticals Inc.LISINOPRIL20mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-2076_9195f48c-59af-471a-8522-1a53845157670378-2076HUMAN PRESCRIPTION DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan Pharmaceuticals Inc.LISINOPRIL40mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-2077_9195f48c-59af-471a-8522-1a53845157670378-2077HUMAN PRESCRIPTION DRUGLisinoprillisinoprilTABLETORAL20020701ANDAANDA076071Mylan Pharmaceuticals Inc.LISINOPRIL30mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-3007_f0a7c860-39a5-433a-a3cb-44add1c485ec0378-3007HUMAN PRESCRIPTION DRUGCaptoprilcaptoprilTABLETORAL19960213ANDAANDA074434Mylan Pharmaceuticals Inc.CAPTOPRIL12.5mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-3012_f0a7c860-39a5-433a-a3cb-44add1c485ec0378-3012HUMAN PRESCRIPTION DRUGCaptoprilcaptoprilTABLETORAL19960213ANDAANDA074434Mylan Pharmaceuticals Inc.CAPTOPRIL25mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-3017_f0a7c860-39a5-433a-a3cb-44add1c485ec0378-3017HUMAN PRESCRIPTION DRUGCaptoprilcaptoprilTABLETORAL19960213ANDAANDA074434Mylan Pharmaceuticals Inc.CAPTOPRIL50mg/1Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]0378-3022_f0a7c860-39a5-433a-a3cb-44add1c485ec0378-3022HUMAN PRESCRIPTION DRUGCaptopri

prime project 1.4 patient safety in the ambulatory care … · web viewprime project 1.4 patient...

Documents